Sustainable Views argues the food sector is treating GLP-1 drugs as a megatrend without folding the shift into its climate strategy.
Recap by typeshit. Full story at Sustainable Views.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
GLP-1 researcher Daniel Drucker links to findings on Lilly's experimental retatrutide and sleep apnea. Details are at the link.
Goodman got sober in 2007 and says the craving shifted to food. Gupta argues a 2025 trial supports the idea, a link to GLP-1 craving research.
Loading…